<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548548</url>
  </required_header>
  <id_info>
    <org_study_id>AVF4200g</org_study_id>
    <secondary_id>BO20904</secondary_id>
    <nct_id>NCT00548548</nct_id>
  </id_info>
  <brief_title>A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer</brief_title>
  <acronym>AVAGAST</acronym>
  <official_title>A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study will compare treatment with bevacizumab in combination with capecitabine and
      cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line
      therapy in patients with locally advanced or metastatic gastric cancer who had not received
      prior chemotherapy for advanced or metastatic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2 arm, randomized, double-blind, multicenter phase III study. Patients will be
      randomized (1:1) to capecitabine/cisplatin plus bevacizumab or capecitabine/cisplatin plus
      placebo. This is an event-driven trial with the primary analysis planned after approximately
      517 deaths had been observed. After the primary analysis, the study will remain open and
      patients can continue with study treatment until progressive disease or earlier at the
      investigator's discretion. After discontinuation of the last patient, the study will end
      globally.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2007</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization until death, up to 26 months</time_frame>
    <description>The primary efficacy endpoint for this study was overall survival (time to death), defined as the time between randomization and the date of death irrespective of the cause of death. Patients for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive. Median survival was estimated by the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From randomization until disease progression or death, up to 26 months.</time_frame>
    <description>Progression-free survival (PFS) is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first. Patients who neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow up for progression of disease. Median PFS was estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival During First-line Therapy</measure>
    <time_frame>From randomization until 28-days after the last study treatment was administered, up to 26 months.</time_frame>
    <description>Progression-free survival (PFS) during first-line therapy is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first and only if it occurs no later than 28 days after last confirmed intake of any study medication and only if it occurs before the start of non-study antineoplastic treatment. Participants who did not progress or die in this interval or were lost to follow-up were censored at the date of the last tumor assessment within this time window. Median PFS was estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>From randomization until disease progression; assessed every 6 weeks for the first year and every 12 weeks thereafter, up to 26 months.</time_frame>
    <description>Time to progression is defined as the time from randomization to the first occurrence of progressive disease (PD). PD was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Patients with no PD at study completion (including those who died before PD) were censored at the date of the last tumor assessment. Median time to PD was estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With a Best Overall Response of Complete or Partial Response</measure>
    <time_frame>From randomization until the end of study, up to 26 months.</time_frame>
    <description>Best overall response during first-line therapy is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response, as determined by the RECIST criteria. CR is defined as the disappearance of all target and non-target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions and no new or progression of non-target lesions, or the disappearance of all target lesions and persistence of one or more non-target lesion(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From randomization to the end of study, up to 26 months</time_frame>
    <description>Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only be calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow up for progression of disease during first line therapy. Median duration of response was estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Disease Control</measure>
    <time_frame>From randomization until the end of study, up to 26 months.</time_frame>
    <description>Disease control for participants with measurable disease was defined as a complete response (CR), partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the RECIST criteria. For participants without measurable disease, disease control was defined as no disease progression for ≥ 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Adverse Events</measure>
    <time_frame>From randomization until 3 months after last dose (up to 26 months)</time_frame>
    <description>The intensity of Adverse Events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 on a five-point scale from Grade 1 (Mild) to Grade 5 (Death). A serious AE (SAE) was defined as any event that is fatal, life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">774</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained prior to any study specific procedures.

          -  Age ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  Life expectancy of at least 3 months.

          -  Able to comply with the protocol.

          -  Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction
             with inoperable, locally advanced, or metastatic disease, not amenable to curative
             therapy.

          -  Measurable disease or non-measurable but evaluable disease, according to the Response
             Evaluation Criteria in Solid Tumours (RECIST).

          -  Patient not receiving anticoagulant medication must have an International normalized
             ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5 x Upper Limit
             of Normal (ULN) within 7 days prior to randomisation.

        Exclusion Criteria:

          -  Previous chemotherapy for locally advanced or metastatic gastric cancer. Patients may
             have received prior neoadjuvant or adjuvant chemotherapy as long as it was completed
             at least 6 months prior to randomisation.

          -  Previous platinum or anti-angiogenic therapy (ie, anti-vascular endothelial growth
             factor [VEGF] or VEGF receptor tyrosine kinase inhibitor, etc.).

          -  Patients with locally advanced disease who are candidates for curative therapy
             (including operation and/or chemotherapy and/or radiotherapy).

          -  Radiotherapy within 28 days of randomisation.

          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to randomisation, or anticipation of the need for major surgery during the
             course of the study treatment (planned elective surgery).

          -  Minor surgical procedures within 2 days prior to randomisation.

          -  Evidence of central nervous system (CNS) metastasis at baseline.

          -  History or evidence upon physical/neurological examination of CNS disease unrelated to
             cancer unless adequately treated with standard medical therapy, eg, uncontrolled
             seizures.

          -  History of another malignancy which could affect compliance with the protocol or
             interpretation of results.

          -  Inadequate bone marrow function.

          -  Inadequate liver function.

          -  Inadequate renal function.

          -  Uncontrolled hypertension or clinically significant (ie, active) cardiovascular
             disease.

          -  Active infection requiring intravenous antibiotics at randomisation.

          -  History or evidence of inherited bleeding diathesis or coagulopathy with the risk of
             bleeding.

          -  Serious or non-healing wound, peptic ulcer, or (incompletely healed) bone fracture.

          -  Active gastrointestinal bleeding.

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months of randomisation.

          -  Neuropathy (eg, impairment of hearing and balance) ≥ grade II according to Common
             Terminology Criteria for Adverse Events (CTCAE) v3.0.

          -  Chronic daily treatment with aspirin or clopidogrel.

          -  Chronic daily treatment with oral corticosteroids; inhaled steroids and short courses
             of oral steroids for anti-emesis or as an appetite stimulant are allowed.

          -  Known hypersensitivity to any of the study drugs or excipients or to Chinese hamster
             ovary cell products or to other recombinant human or humanised antibodies.

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency.

          -  Evidence of any other disease, metabolic or psychological dysfunction, physical
             examination finding, or clinical laboratory finding giving reasonable suspicion of a
             disease or condition that contraindicates use of an investigational drug, or that may
             affect patient compliance with the study, or place the patient at high risk from
             treatment complications.

          -  Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C
             virus (HCV).

          -  Pregnant or lactating females.

          -  Women of childbearing potential not using effective nonhormonal (intrauterine
             contraceptive device, barrier method of contraception in conjunction with spermicidal
             jelly, or surgically sterile) means of contraception.

          -  Sexually active men unwilling to practice contraception during the study.

          -  Current or recent (within the 28 days prior to randomisation) treatment with another
             investigational drug or participation in another investigational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hedrick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tower Cancer Research Fnd</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211-1850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenmar Research Institute LLC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center Onc</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Assoc</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Inst</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2007</study_first_submitted>
  <study_first_submitted_qc>October 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2007</study_first_posted>
  <results_first_submitted>December 15, 2011</results_first_submitted>
  <results_first_submitted_qc>December 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2012</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avastin</keyword>
  <keyword>Metastatic Adenocarcinoma</keyword>
  <keyword>AVAGAST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab</title>
          <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="387"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="383"/>
                <participants group_id="P2" count="384"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="386">Four patients randomized to placebo received single doses of bevacizumab in error.</participants>
                <participants group_id="P2" count="381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25">Completed treatment discontinuation form was not completed; patient was counted alive on treatment.</participants>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="366"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="348"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab</title>
          <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="387"/>
            <count group_id="B2" value="387"/>
            <count group_id="B3" value="774"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>The primary efficacy endpoint for this study was overall survival (time to death), defined as the time between randomization and the date of death irrespective of the cause of death. Patients for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive. Median survival was estimated by the Kaplan-Meier method.</description>
        <time_frame>From randomization until death, up to 26 months</time_frame>
        <population>The Intent-to-Treat population, including all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The primary efficacy endpoint for this study was overall survival (time to death), defined as the time between randomization and the date of death irrespective of the cause of death. Patients for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive. Median survival was estimated by the Kaplan-Meier method.</description>
          <population>The Intent-to-Treat population, including all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="11.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="10.1" lower_limit="9.0" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival (PFS) is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first. Patients who neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow up for progression of disease. Median PFS was estimated using the Kaplan-Meier method.</description>
        <time_frame>From randomization until disease progression or death, up to 26 months.</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival (PFS) is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first. Patients who neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow up for progression of disease. Median PFS was estimated using the Kaplan-Meier method.</description>
          <population>Intent to treat</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="5.9" upper_limit="7.1"/>
                    <measurement group_id="O2" value="5.3" lower_limit="4.4" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival During First-line Therapy</title>
        <description>Progression-free survival (PFS) during first-line therapy is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first and only if it occurs no later than 28 days after last confirmed intake of any study medication and only if it occurs before the start of non-study antineoplastic treatment. Participants who did not progress or die in this interval or were lost to follow-up were censored at the date of the last tumor assessment within this time window. Median PFS was estimated using the Kaplan-Meier method.</description>
        <time_frame>From randomization until 28-days after the last study treatment was administered, up to 26 months.</time_frame>
        <population>Intent-to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival During First-line Therapy</title>
          <description>Progression-free survival (PFS) during first-line therapy is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first and only if it occurs no later than 28 days after last confirmed intake of any study medication and only if it occurs before the start of non-study antineoplastic treatment. Participants who did not progress or die in this interval or were lost to follow-up were censored at the date of the last tumor assessment within this time window. Median PFS was estimated using the Kaplan-Meier method.</description>
          <population>Intent-to treat.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="6.2" upper_limit="7.3"/>
                    <measurement group_id="O2" value="5.4" lower_limit="4.7" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Time to progression is defined as the time from randomization to the first occurrence of progressive disease (PD). PD was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Patients with no PD at study completion (including those who died before PD) were censored at the date of the last tumor assessment. Median time to PD was estimated using the Kaplan-Meier method.</description>
        <time_frame>From randomization until disease progression; assessed every 6 weeks for the first year and every 12 weeks thereafter, up to 26 months.</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Time to progression is defined as the time from randomization to the first occurrence of progressive disease (PD). PD was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Patients with no PD at study completion (including those who died before PD) were censored at the date of the last tumor assessment. Median time to PD was estimated using the Kaplan-Meier method.</description>
          <population>Intent-to-treat</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="6.5" upper_limit="7.6"/>
                    <measurement group_id="O2" value="5.6" lower_limit="5.1" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With a Best Overall Response of Complete or Partial Response</title>
        <description>Best overall response during first-line therapy is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response, as determined by the RECIST criteria. CR is defined as the disappearance of all target and non-target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions and no new or progression of non-target lesions, or the disappearance of all target lesions and persistence of one or more non-target lesion(s).</description>
        <time_frame>From randomization until the end of study, up to 26 months.</time_frame>
        <population>Measurable Disease Population, including all randomized participants with measurable disease (per RECIST) for gastric cancer at baseline. Patients were analyzed according to the treatment groups to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With a Best Overall Response of Complete or Partial Response</title>
          <description>Best overall response during first-line therapy is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response, as determined by the RECIST criteria. CR is defined as the disappearance of all target and non-target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions and no new or progression of non-target lesions, or the disappearance of all target lesions and persistence of one or more non-target lesion(s).</description>
          <population>Measurable Disease Population, including all randomized participants with measurable disease (per RECIST) for gastric cancer at baseline. Patients were analyzed according to the treatment groups to which they were randomized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only be calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow up for progression of disease during first line therapy. Median duration of response was estimated using the Kaplan-Meier method.</description>
        <time_frame>From randomization to the end of study, up to 26 months</time_frame>
        <population>Participants with measurable disease at baseline who had a best overall response of complete response or partial response, and for whom duration of response data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only be calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow up for progression of disease during first line therapy. Median duration of response was estimated using the Kaplan-Meier method.</description>
          <population>Participants with measurable disease at baseline who had a best overall response of complete response or partial response, and for whom duration of response data was available.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.2" upper_limit="8.3"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.6" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Disease Control</title>
        <description>Disease control for participants with measurable disease was defined as a complete response (CR), partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the RECIST criteria. For participants without measurable disease, disease control was defined as no disease progression for ≥ 6 weeks.</description>
        <time_frame>From randomization until the end of study, up to 26 months.</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Disease Control</title>
          <description>Disease control for participants with measurable disease was defined as a complete response (CR), partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the RECIST criteria. For participants without measurable disease, disease control was defined as no disease progression for ≥ 6 weeks.</description>
          <population>Intent-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with Disease Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants without Disease Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adverse Events</title>
        <description>The intensity of Adverse Events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 on a five-point scale from Grade 1 (Mild) to Grade 5 (Death). A serious AE (SAE) was defined as any event that is fatal, life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.</description>
        <time_frame>From randomization until 3 months after last dose (up to 26 months)</time_frame>
        <population>Safety population, including all patients randomized and exposed to study medication (defined as any one component of the combination). Patients are assigned to treatment groups based on the treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Adverse Events</title>
          <description>The intensity of Adverse Events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 on a five-point scale from Grade 1 (Mild) to Grade 5 (Death). A serious AE (SAE) was defined as any event that is fatal, life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.</description>
          <population>Safety population, including all patients randomized and exposed to study medication (defined as any one component of the combination). Patients are assigned to treatment groups based on the treatment they actually received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3/4/5 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths not due to Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of very first drug intake until 91 day(s) after very last drug intake.</time_frame>
      <desc>Safety population: All randomized participants who were exposed to study medication (defined as any one component of the combination).</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab</title>
          <description>Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>MICROANGIOPATHIC HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>SPLENIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTRIC PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>OBSTRUCTION GASTRIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ACUTE ABDOMEN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DUODENAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTRIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ILEAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CATHETER THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPERPYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>STENT MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>BILE DUCT STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>BACILLUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PRIMARY ATYPICAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>AFFERENT LOOP SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>STENT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>STOMA SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>BLOOD SODIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>TUMOUR NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>TUMOUR PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY TOXIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>RENAL SALT-WASTING SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PEMPHIGOID</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>VASOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="378" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="373" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GINGIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>CREATININE RENAL CLEARANCE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PALMAR−PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>SKIN HYPERPIGMENTATION</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>PIGMENTATION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="381"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="381"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

